GRAPPA 2015 Research and Education Project Reports

2016 ◽  
Vol 43 (5) ◽  
pp. 979-985 ◽  
Author(s):  
Philip J. Mease ◽  
Philip S. Helliwell ◽  
Wolf-Henning Boehncke ◽  
Laura C. Coates ◽  
Oliver FitzGerald ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Joint Damage ◽  
Treatment Recommendations ◽  
Musculoskeletal Disease ◽  
Education Project ◽  
Publication Committee ◽  
Structural Joint ◽  
Research And Education

At the 2015 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), attendees were presented with brief updates on several ongoing initiatives, including educational projects. Updates were presented on the treatment recommendations project, the development of simple criteria to identify inflammatory musculoskeletal disease, new patient/physician Delphi exercises, and BIODAM (identifying biomarkers that predict progressive structural joint damage). The publication committee also gave a report. Herein we summarize those project updates.

GRAPPA Treatment Recommendations: An Update from the GRAPPA 2014 Annual Meeting and GRAPPA Meeting Adjacent to the 2014 ACR Meeting

2015 ◽  
Vol 42 (6) ◽  
pp. 1052-1055 ◽  
Author(s):  
Laura C. Coates ◽  
Arthur F. Kavanaugh ◽  
Philip J. Mease ◽  
Christopher T. Ritchlin
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Previous Treatment ◽  
Treatment Recommendations ◽  
Treatment Algorithms ◽  
Assessment Development ◽  
American College Of Rheumatology ◽  
Final Treatment ◽  
Literature Reviews ◽  
Associated Conditions

At the 2014 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members discussed an update of their previous treatment recommendations published in 2009. Domain subcommittees representing the different aspects of psoriatic arthritis (PsA) had been reconvened in 2013 and a new group was formed that focused on PsA comorbidities and associated conditions. A combined literature review was completed in February 2013 followed by individual group literature reviews and analyses. Articles from each of these subcommittees were published in 2014, updating the evidence for individual therapies in PsA. At their 2014 annual meeting, GRAPPA members discussed their plans for a summary article on treatment recommendations, finalized the Grading of Recommendations Assessment, Development and Evaluation (GRADE)-formatted recommendations for individual drugs within the domain subcommittees, and presented these for debate. Modifications to the GRAPPA grid were also discussed in breakout groups and presented to the full membership. At the GRAPPA meeting adjacent to the 2014 American College of Rheumatology meeting, a new GRAPPA treatment schema was proposed to replace the original GRAPPA grid. Each domain subcommittee discussed treatment algorithms based on their GRADE recommendations for inclusion in the final treatment recommendations article, which will be submitted in 2015.

Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks

2017 ◽  
Vol 1 ◽  
pp. s28
Author(s):  
Desiree Van der Heijde ◽  
Masato Okada ◽  
Chin Lee ◽  
Catherine L Shuler ◽  
Suchitrita Rathmann ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Radiographic Progression ◽  
Joint Damage ◽  
Structural Joint

Abstract Not Available

GRAPPA 2013 Annual Meeting, Rheumatology Updates: Psoriatic Arthritis (PsA) Biomarker Project, Arthritis Mutilans, PsA-Peripheral Spondyloarthritis Epidemiology Project

2014 ◽  
Vol 41 (6) ◽  
pp. 1244-1248 ◽  
Author(s):  
Oliver FitzGerald ◽  
Philip J. Mease ◽  
Philip S. Helliwell ◽  
Vinod Chandran
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Joint Damage ◽  
Classification Criteria ◽  
Undifferentiated Arthritis ◽  
Psoriatic Disease ◽  
Inflammatory Bowel ◽  
Peripheral Spondyloarthritis ◽  
Arthritis Mutilans ◽  
Made In

At the 2013 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), several key GRAPPA projects on musculoskeletal aspects of psoriatic disease were reviewed. In this article, lead investigators summarize the progress made in a multicenter study, the PsA BioDam (Psoriatic Arthritis Biomarkers for Joint Damage), to identify soluble biomarkers for joint damage, as well as developing classification criteria for arthritis mutilans. Also reviewed are concepts and rationale behind a proposal to study classification criteria for peripheral spondyloarthritis, including PsA, reactive arthritis, inflammatory bowel disease-associated arthritis, and undifferentiated arthritis.

scholarly journals International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting

2017 ◽  
Vol 44 (5) ◽  
pp. 684-685 ◽  
Author(s):  
Laura C. Coates ◽  
Vinod Chandran ◽  
Alexis Ogdie ◽  
Denis O’Sullivan ◽  
Mel Brooke ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
South America ◽  
Annual Meeting ◽  
Treatment Recommendations ◽  
Reference Guide ◽  
Resource Poor ◽  
International League

At the 2016 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the treatment recommendations committee summarized its work and presented its plans for future updates. The committee announced a partnership between GRAPPA and Guideline Central to develop a pocket reference guide to the treatment recommendations. Because key new data appear regularly, the group discussed publishing periodic updates of the recommendations online through the GRAPPA Website as well as a goal of publishing another major update of the recommendations in 2020. The committee also announced that 2 GRAPPA members were awarded a grant from the International League of Associations for Rheumatology to look at potential adaptations of international treatment recommendations for resource-poor settings, particularly in South America and Africa.

Treatments for Psoriatic Arthritis, a Guide for Patients Written by Fellow Patients: A Report from the GRAPPA 2016 Annual Meeting

2017 ◽  
Vol 44 (5) ◽  
pp. 686-687 ◽  
Author(s):  
Denis O’Sullivan ◽  
Ingrid Steinkoenig ◽  
Mel Brooke
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Treatment Recommendations ◽  
Diagnosis And Treatment ◽  
Treatment Needs ◽  
Potential Patient

In 2016, members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) published their updated Treatment Recommendations for Psoriatic Arthritis. This paper describes how a patient-oriented guide to those treatment recommendations was developed by GRAPPA’s patient research partners (PRP). We describe how the PRP developed a process for creating and implementing the guide. We also describe how we evaluated the diversity of the guide’s potential patient audience, i.e., where each individual was in their diagnosis and treatment needs, and how we made the patient guide attractive, readable, and available to as broad a patient audience as possible.

Distinguishing Inflammatory from Noninflammatory Arthritis, Enthesitis, and Dactylitis in Psoriatic Arthritis: A Report from the GRAPPA 2010 Annual Meeting: Table 1.

2012 ◽  
Vol 39 (2) ◽  
pp. 415-417 ◽  
Author(s):  
PHILIP J. MEASE
Keyword(s):  
Primary Care ◽  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Inflammatory Arthritis ◽  
Primary Care Providers ◽  
Musculoskeletal Disease ◽  
Care Providers ◽  
Key Variables

The most widely applied criteria for classifying psoriatic arthritis (PsA) are the CASPAR (ClASsification of Psoriatic ARthritis) criteria. A patient who fulfills the CASPAR criteria must have evidence of inflammatory arthritis, enthesitis, or spondylitis, and may have an inflammatory musculoskeletal component, dactylitis. Although the criteria were developed by rheumatologists, not all patients with PsA are seen by rheumatologists. Thus, it is important for clinicians such as dermatologists, primary care providers, physiatrists, and orthopedists, and patients themselves, to be able to recognize the presence of inflammatory musculoskeletal disease and distinguish it from degenerative or traumatic musculoskeletal disease. At their 2010 annual meeting, members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) discussed the steps they are taking to define the key variables that must be present to distinguish inflammatory arthritis, enthesitis, and dactylitis from degenerative, traumatic, mechanical, or infectious forms of these conditions.

scholarly journals Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks

2018 ◽  
Vol 2 ◽  
pp. S14
Author(s):  
Desiree Van der Heijde ◽  
Masato Okada ◽  
Chin Lee ◽  
Catherine L Shuler ◽  
Suchitrita Rathmann ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Radiographic Progression ◽  
Joint Damage ◽  
Structural Joint

Abstract not available. Disclosures: Study sponsored by Eli Lilly and Company. Copyright 2018 SKIN

scholarly journals GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting

2021 ◽  
pp. jrheum.201681
Author(s):  
Laura C. Coates ◽  
Nadia Corp ◽  
Danielle A. van der Windt ◽  
Enrique R. Soriano ◽  
Arthur Kavanaugh
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Treatment Recommendations ◽  
Optimal Treatment ◽  
Treatment Approaches ◽  
Domain Specific ◽  
Literature Searches ◽  
The Many ◽  
Systematic Literature Searches

Throughout 2020, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has been working to update the GRAPPA treatment recommendations for psoriasis and psoriatic arthritis (PsA). The planned methodology for this update was published previously, and herein we provide an update on progress so far, including details of the systematic literature searches undertaken. GRAPPA is committed to regular updates of its treatment recommendations to incorporate the many significant therapeutic advances that have taken place in the PsA literature since the previous recommendation publication in 2015. The development and updating of treatment recommendations for optimal treatment approaches for patients with PsA has been an important mission of the GRAPPA since its inception. GRAPPA is currently finalizing domain-specific recommendations with an aim to produce updated treatment recommendations for publication in 2021.

On Defining Musculoskeletal Inflammation: A Report from the GRAPPA 2011 Annual Meeting

2012 ◽  
Vol 39 (11) ◽  
pp. 2214-2215 ◽  
Author(s):  
AMIT GARG ◽  
DAFNA D. GLADMAN ◽  
PHILIP J. MEASE
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Inflammatory Arthritis ◽  
Classification Criteria ◽  
Musculoskeletal Disease ◽  
Group Discussions ◽  
Diagnostic Measure ◽  
Breakout Group

At the 2011 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members discussed the need to develop a framework for defining inflammatory arthritis, enthesitis, dactylitis, and spondylitis, particularly as they relate to psoriatic arthritis (PsA). GRAPPA members first addressed this subject at their 2010 meeting, where the CASPAR (ClASsification of Psoriatic ARthritis) criteria were discussed. Although these are classification criteria, the CASPAR are also often applied as a diagnostic measure by clinicians screening for PsA, particularly its core criterion: recognizing the presence of inflammatory musculoskeletal disease. In breakout group discussions, GRAPPA members discussed the difficulties in recognizing overlapping or mimicking features that may result in underdiagnosing or misdiagnosing PsA.

Sign in / Sign up

Export Citation Format

Share Document